Gufic Biosciences Limited (BOM:509079)

Market Cap	36.20B
Revenue (ttm)	8.10B
Net Income (ttm)	819.76M
Shares Out	100.28M
EPS (ttm)	8.17
PE Ratio	44.15
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	5,450
Average Volume	6,580
Open	353.00
Previous Close	345.75
Day's Range	342.25 - 367.65
52-Week Range	278.00 - 501.10
Beta	0.72
RSI	65.71
Earnings Date	May 29, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,491
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.